{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:42:30Z","timestamp":1793911350517,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Feist-Weiller Cancer Center at Louisiana State University Health Shreveport"},{"name":"Research Center,  Shahjalal University of Science and Technology, Sylhet-3114, Bangladesh"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16614-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:05:45Z","timestamp":1758884745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Md. Niaz","family":"Morshed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorwer Alam","family":"Parvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakibul Islam","family":"Akanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manash Kumar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannatul","family":"Fardous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksudul","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar E.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Jakir","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"16614_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty, S., Fisher, P. B. & Sarkar, D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv. Cancer Res. 149, 1\u201361 (2021).","journal-title":"Adv. Cancer Res."},{"issue":"5","key":"16614_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.medj.2021.03.002","volume":"2","author":"S Gallage","year":"2021","unstructured":"Gallage, S. et al. The therapeutic landscape of hepatocellular carcinoma. Med. 2(5), 505\u2013552 (2021).","journal-title":"Med."},{"issue":"19","key":"16614_CR3","doi-asserted-by":"publisher","first-page":"10271","DOI":"10.3390\/ijms221910271","volume":"22","author":"SK Lee","year":"2021","unstructured":"Lee, S. K. et al. Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma. Int. J. Mol. Sci. 22(19), 10271 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"16614_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00432-021-03826-w","volume":"148","author":"A Raja","year":"2022","unstructured":"Raja, A. & Haq, F. Molecular classification of hepatocellular carcinoma: Prognostic importance and clinical applications. J. Cancer Res. Clin. Oncol. 148(1), 15\u201329 (2022).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"16614_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.acr.2020.10.002","volume":"149","author":"T Garcia-Lezana","year":"2021","unstructured":"Garcia-Lezana, T., Lopez-Canovas, J. L. & Villanueva, A. Signaling pathways in hepatocellular carcinoma. Adv. Cancer Res. 149, 63\u2013101 (2021).","journal-title":"Adv. Cancer Res."},{"issue":"8","key":"16614_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5306\/wjco.v11.i8.589","volume":"11","author":"AK Chow","year":"2020","unstructured":"Chow, A. K., Yau, S. W. & Ng, L. Novel molecular targets in hepatocellular carcinoma. World J. Clin. Oncol. 11(8), 589\u2013605 (2020).","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"16614_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","volume":"40","author":"XY Luo","year":"2021","unstructured":"Luo, X. Y., Wu, K. M. & He, X. X. Advances in drug development for hepatocellular carcinoma: Clinical trials and potential therapeutic targets. J. Exp. Clin. Cancer Res. 40(1), 172 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"16614_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clinre.2017.12.006","volume":"42","author":"JJG Marin","year":"2018","unstructured":"Marin, J. J. G. et al. Molecular bases of the poor response of liver cancer to chemotherapy. Clin. Res. Hepatol. Gastroenterol. 42(3), 182\u2013192 (2018).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"6","key":"16614_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3390\/cancers12061663","volume":"12","author":"JJG Marin","year":"2020","unstructured":"Marin, J. J. G. et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers (Basel) 12(6), 1663 (2020).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"16614_CR10","doi-asserted-by":"publisher","first-page":"14784","DOI":"10.1038\/s41598-021-94019-5","volume":"11","author":"IJ Campeanu","year":"2021","unstructured":"Campeanu, I. J. et al. Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer. Sci. Rep. 11(1), 14784 (2021).","journal-title":"Sci. Rep."},{"issue":"11","key":"16614_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00109-019-01830-9","volume":"97","author":"QH Tian","year":"2019","unstructured":"Tian, Q. H. et al. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. J. Mol. Med. (Berl) 97(11), 1535\u20131545 (2019).","journal-title":"J. Mol. Med. (Berl)"},{"issue":"12","key":"16614_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.661","volume":"11","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. METTL1 promotes hepatocarcinogenesis via m. Clin. Transl. Med. 11(12), e661 (2021).","journal-title":"Clin. Transl. Med."},{"issue":"8","key":"16614_CR13","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/cam4.2918","volume":"9","author":"Y Lin","year":"2020","unstructured":"Lin, Y. et al. METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma. Cancer Med. 9(8), 2859\u20132867 (2020).","journal-title":"Cancer Med."},{"issue":"13","key":"16614_CR14","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.7150\/thno.42539","volume":"10","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma. Theranostics 10(13), 5671\u20135686 (2020).","journal-title":"Theranostics"},{"issue":"1","key":"16614_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3892\/ijo.2021.5294","volume":"60","author":"A Bolatkan","year":"2022","unstructured":"Bolatkan, A. et al. Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules. Int. J. Oncol. 60(1), 4 (2022).","journal-title":"Int. J. Oncol."},{"key":"16614_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.665192","volume":"11","author":"TH Li","year":"2021","unstructured":"Li, T. H. et al. Identification METTL18 as a potential prognosis biomarker and associated with immune infiltrates in hepatocellular carcinoma. Front. Oncol. 11, 665192 (2021).","journal-title":"Front. Oncol."},{"issue":"1","key":"16614_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s11658-022-00342-8","volume":"27","author":"YZ Dai","year":"2022","unstructured":"Dai, Y. Z. et al. METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m. Cell Mol. Biol. Lett. 27(1), 41 (2022).","journal-title":"Cell Mol. Biol. Lett."},{"issue":"1","key":"16614_CR18","doi-asserted-by":"publisher","first-page":"10755","DOI":"10.1038\/s41598-023-37807-5","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang, L. & Peng, J.-L. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment. Sci. Rep. 13(1), 10755 (2023).","journal-title":"Sci. Rep."},{"issue":"1","key":"16614_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41420-023-01723-4","volume":"9","author":"F Bi","year":"2023","unstructured":"Bi, F. et al. METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition. Cell Death Discovery 9(1), 428 (2023).","journal-title":"Cell Death Discovery"},{"issue":"7860","key":"16614_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova, E. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593(7860), 597\u2013601 (2021).","journal-title":"Nature"},{"key":"16614_CR21","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/S0959-8049(22)01128-5","volume":"174","author":"Y Ofir-Rosenfeld","year":"2022","unstructured":"Ofir-Rosenfeld, Y. et al. STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade. Eur. J. Cancer 174, S123 (2022).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"16614_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0021-9258(19)68144-5","volume":"257","author":"F Creusot","year":"1982","unstructured":"Creusot, F., Acs, G. & Christman, J. K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2\u2019-deoxycytidine. J. Biol. Chem. 257(4), 2041\u20132048 (1982).","journal-title":"J. Biol. Chem."},{"issue":"10","key":"16614_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi, M. B. et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat. Cancer 2(10), 1002\u20131017 (2021).","journal-title":"Nat. Cancer"},{"key":"16614_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.127908","volume":"40","author":"S Huang","year":"2021","unstructured":"Huang, S. et al. A novel class of selective non-nucleoside inhibitors of human DNA methyltransferase 3A. Bioorg. Med. Chem. Lett. 40, 127908 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"16614_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu, C. et al. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: Mechanism and clinical application. Clin. Epigenetics 13(1), 166 (2021).","journal-title":"Clin. Epigenetics"},{"issue":"19","key":"16614_CR26","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1002\/cmdc.202100291","volume":"16","author":"EV Moroz-Omori","year":"2021","unstructured":"Moroz-Omori, E. V. et al. METTL3 inhibitors for epitranscriptomic modulation of cellular processes. Chem. Med. Chem. 16(19), 3035\u20133043 (2021).","journal-title":"Chem. Med. Chem."},{"issue":"6","key":"16614_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41594-021-00606-5","volume":"28","author":"J Li","year":"2021","unstructured":"Li, J. & Gregory, R. I. Mining for METTL3 inhibitors to suppress cancer. Nat. Struct. Mol. Biol. 28(6), 460\u2013462 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"16614_CR28","first-page":"783","volume":"83","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. et al. Discovery of substituted indole derivatives as allosteric inhibitors of m. Drug Dev. Res. 83(3), 783\u2013799 (2022).","journal-title":"Drug Dev. Res."},{"issue":"4","key":"16614_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/ph15040440","volume":"15","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. et al. Eltrombopag as an allosteric inhibitor of the METTL3-14 complex affecting the m. Pharmaceuticals (Basel) 15(4), 440 (2022).","journal-title":"Pharmaceuticals (Basel)"},{"key":"16614_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.878135","volume":"13","author":"Y Du","year":"2022","unstructured":"Du, Y. et al. Discovery of METTL3 small molecule inhibitors by virtual screening of natural products. Front. Pharmacol. 13, 878135 (2022).","journal-title":"Front. Pharmacol."},{"issue":"17","key":"16614_CR31","doi-asserted-by":"publisher","first-page":"12738","DOI":"10.1021\/acs.jmedchem.1c00773","volume":"64","author":"A Dolbois","year":"2021","unstructured":"Dolbois, A. et al. 1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors. J. Med. Chem. 64(17), 12738\u201312760 (2021).","journal-title":"J. Med. Chem."},{"issue":"9","key":"16614_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/cmdc.202000011","volume":"15","author":"RK Bedi","year":"2020","unstructured":"Bedi, R. K. et al. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem 15(9), 744\u2013748 (2020).","journal-title":"ChemMedChem"},{"issue":"D1","key":"16614_CR33","first-page":"D271","volume":"45","author":"PW Rose","year":"2017","unstructured":"Rose, P. W. et al. The RCSB protein data bank: Integrative view of protein, gene and 3D structural information. Nucleic Acids Res. 45(D1), D271\u2013D281 (2017).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"16614_CR34","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"S Kim","year":"2021","unstructured":"Kim, S. et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res. 49(D1), D1388\u2013D1395 (2021).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"16614_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"issue":"D1","key":"16614_CR36","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"U Consortium","year":"2023","unstructured":"Consortium, U. UniProt: The Universal protein knowledgebase in 2023. Nucleic Acids Res. 51(D1), D523\u2013D531 (2023).","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"16614_CR37","doi-asserted-by":"publisher","first-page":"W443","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"S Salentin","year":"2015","unstructured":"Salentin, S. et al. PLIP: Fully automated protein-ligand interaction profiler. Nucleic Acids Res. 43(W1), W443\u2013W447 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"16614_CR38","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.drudis.2021.12.017","volume":"27","author":"N Ye","year":"2022","unstructured":"Ye, N., Yang, Z. & Liu, Y. Applications of density functional theory in COVID-19 drug modeling. Drug Discov. Today 27(5), 1411\u20131419 (2022).","journal-title":"Drug Discov. Today"},{"key":"16614_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.softx.2017.11.002","volume":"7","author":"S Lehtola","year":"2018","unstructured":"Lehtola, S. et al. Recent developments in libxc\u2014A comprehensive library of functionals for density functional theory. SoftwareX 7, 1\u20135 (2018).","journal-title":"SoftwareX"},{"key":"16614_CR40","doi-asserted-by":"publisher","first-page":"e1606","DOI":"10.1002\/wcms.1606","volume":"12","author":"F Neese","year":"2022","unstructured":"Neese, F. Software update: The ORCA program system\u2014Version 50. Wiley Interdiscip. Rev. Comput. Mol. Sci. 12, e1606 (2022).","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"issue":"1","key":"16614_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell, M. D. et al. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminformat. 4(1), 17 (2012).","journal-title":"J. Cheminformat."},{"key":"16614_CR42","doi-asserted-by":"publisher","first-page":"137869","DOI":"10.1016\/j.cplett.2020.137869","volume":"757","author":"S Bagheri Novir","year":"2020","unstructured":"Bagheri Novir, S. & Aram, M. R. Quantum mechanical simulation of chloroquine drug interaction with C60 fullerene for treatment of COVID-19. Chem. Phys. Lett. 757, 137869 (2020).","journal-title":"Chem. Phys. Lett."},{"issue":"22","key":"16614_CR43","doi-asserted-by":"publisher","first-page":"8440","DOI":"10.1073\/pnas.83.22.8440","volume":"83","author":"RG Pearson","year":"1986","unstructured":"Pearson, R. G. Absolute electronegativity and hardness correlated with molecular orbital theory. Proc. Natl. Acad. Sci. U. S. A. 83(22), 8440\u20138441 (1986).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16614_CR44","doi-asserted-by":"crossref","unstructured":"Parr, R. G. Density functional theory of atoms and molecules. in Horizons of Quantum Chemistry (Springer, 1980).","DOI":"10.1007\/978-94-009-9027-2_2"},{"key":"16614_CR45","doi-asserted-by":"publisher","first-page":"W223","DOI":"10.1093\/nar\/gkn187","volume":"36","author":"D Schneidman-Duhovny","year":"2008","unstructured":"Schneidman-Duhovny, D. et al. PharmaGist: A webserver for ligand-based pharmacophore detection. Nucleic Acids Res. 36, W223\u2013W228 (2008).","journal-title":"Nucleic Acids Res."},{"key":"16614_CR46","doi-asserted-by":"publisher","first-page":"W409","DOI":"10.1093\/nar\/gks378","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes, D. R. & Camacho, C. J. ZINCPharmer: Pharmacophore search of the ZINC database. Nucleic Acids Res. 40, W409\u2013W414 (2012).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"16614_CR47","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7(1), 42717 (2017).","journal-title":"Sci. Rep."},{"issue":"11","key":"16614_CR48","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1021\/ci300367a","volume":"52","author":"F Cheng","year":"2012","unstructured":"Cheng, F. et al. admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. J. Chem. Inf. Model. 52(11), 3099\u20133105 (2012).","journal-title":"J. Chem. Inf. Model."},{"key":"16614_CR49","doi-asserted-by":"publisher","first-page":"W270","DOI":"10.1093\/nar\/gkr366","volume":"39","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39, W270\u2013W277 (2011).","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"16614_CR50","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. CB-Dock2: Improved protein\u2013ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 50(W1), W159\u2013W164 (2022).","journal-title":"Nucleic Acids Res."},{"key":"16614_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111742","volume":"140","author":"M Hasan","year":"2021","unstructured":"Hasan, M. et al. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach. Biomed. Pharmacother. 140, 111742 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"16614_CR52","doi-asserted-by":"crossref","unstructured":"Abraham, M., et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 2015. 1.","DOI":"10.1016\/j.softx.2015.06.001"},{"issue":"Pt 8","key":"16614_CR53","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1107\/S0907444904011679","volume":"60","author":"AW Sch\u00fcttelkopf","year":"2004","unstructured":"Sch\u00fcttelkopf, A. W. & van Aalten, D. M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60(Pt 8), 1355\u20131363 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"5","key":"16614_CR54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert. Opin. Drug Discov. 10(5), 449\u2013461 (2015).","journal-title":"Expert. Opin. Drug Discov."},{"key":"16614_CR55","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2020.00733","volume":"11","author":"W Cui","year":"2020","unstructured":"Cui, W. et al. Discovering anti-cancer drugs via computational methods. Front. Pharmacol. 11, 733 (2020).","journal-title":"Front. Pharmacol."},{"key":"16614_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2020.128715","volume":"1220","author":"MA Mumit","year":"2020","unstructured":"Mumit, M. A. et al. DFT studies on vibrational and electronic spectra, HOMO-LUMO, MEP, HOMA, NBO and molecular docking analysis of benzyl-3-N-(2,4,5-trimethoxyphenylmethylene)hydrazinecarbodithioate. J. Mol. Struct. 1220, 128715 (2020).","journal-title":"J. Mol. Struct."},{"issue":"11","key":"16614_CR57","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cmdc.201600182","volume":"11","author":"A Daina","year":"2016","unstructured":"Daina, A. & Zoete, V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11(11), 1117\u20131121 (2016).","journal-title":"ChemMedChem"},{"issue":"3","key":"16614_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/cancers14030621","volume":"14","author":"B Cucarull","year":"2022","unstructured":"Cucarull, B. et al. Hepatocellular carcinoma: Molecular pathogenesis and therapeutic advances. Cancers (Basel) 14(3), 621 (2022).","journal-title":"Cancers (Basel)"},{"issue":"19","key":"16614_CR59","doi-asserted-by":"publisher","first-page":"10774","DOI":"10.3390\/ijms221910774","volume":"22","author":"N Juaid","year":"2021","unstructured":"Juaid, N. et al. Anti-hepatocellular carcinoma biomolecules: Molecular targets insights. Int. J. Mol. Sci. 22(19), 10774 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"16614_CR60","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm, S. et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5(10), 835\u2013844 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"16614_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","volume":"5","author":"W Zhang","year":"2017","unstructured":"Zhang, W. & Xu, J. DNA methyltransferases and their roles in tumorigenesis. Biomarker Res. 5(1), 1 (2017).","journal-title":"Biomarker Res."},{"issue":"1","key":"16614_CR62","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/s41598-023-28078-1","volume":"13","author":"L Janacova","year":"2023","unstructured":"Janacova, L. et al. Catechol-O-methyl transferase suppresses cell invasion and interplays with MET signaling in estrogen dependent breast cancer. Sci. Rep. 13(1), 1285 (2023).","journal-title":"Sci. Rep."},{"key":"16614_CR63","doi-asserted-by":"crossref","unstructured":"Kremling, V., et al. SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery. 2024, eLife Sciences Publications, Ltd.","DOI":"10.1101\/2024.03.13.583470"},{"issue":"3","key":"16614_CR64","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1021\/acschembio.7b00890","volume":"13","author":"F Ye","year":"2018","unstructured":"Ye, F. et al. Biochemical studies and molecular dynamic simulations reveal the molecular basis of conformational changes in DNA Methyltransferase-1. ACS Chem. Biol. 13(3), 772\u2013781 (2018).","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"16614_CR65","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00432-021-03669-5","volume":"147","author":"A Ahmed","year":"2021","unstructured":"Ahmed, A. et al. Aurora B kinase: A potential drug target for cancer therapy. J. Cancer Res. Clin. Oncol. 147(8), 2187\u20132198 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"16614_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110434","volume":"99","author":"S Anwar","year":"2022","unstructured":"Anwar, S. et al. Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. Cell Signal 99, 110434 (2022).","journal-title":"Cell Signal"},{"issue":"3","key":"16614_CR67","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","volume":"24","author":"T Zubair","year":"2023","unstructured":"Zubair, T. & Bandyopadhyay, D. Small molecule EGFR inhibitors as anti-cancer agents: Discovery, mechanisms of action, and opportunities. Int. J. Mol. Sci. 24(3), 2651 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"16614_CR68","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s12276-025-01415-2","volume":"57","author":"S Park","year":"2025","unstructured":"Park, S. & Hall, M. N. Metabolic reprogramming in hepatocellular carcinoma: Mechanisms and therapeutic implications. Exp. Mol. Med. 57(3), 515\u2013523 (2025).","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"16614_CR69","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen, M. et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67(6), 2254\u20132270 (2018).","journal-title":"Hepatology"},{"issue":"3","key":"16614_CR70","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","volume":"62","author":"S Lin","year":"2016","unstructured":"Lin, S. et al. The m(6)A Methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell 62(3), 335\u2013345 (2016).","journal-title":"Mol. Cell"},{"key":"16614_CR71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omto.2022.05.009","volume":"26","author":"W Cheng","year":"2022","unstructured":"Cheng, W. et al. Novel roles of METTL1\/WDR4 in tumor via m7G methylation. Mol. Ther. Oncol. 26, 27\u201334 (2022).","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"16614_CR72","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-022-02539-5","volume":"22","author":"C Ma","year":"2022","unstructured":"Ma, C. et al. The molecular mechanism of METTL3 promoting the malignant progression of lung cancer. Cancer Cell Int. 22(1), 133 (2022).","journal-title":"Cancer Cell Int."},{"issue":"12","key":"16614_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.675","volume":"11","author":"X Ying","year":"2021","unstructured":"Ying, X. et al. METTL1-m(7) G-EGFR\/EFEMP1 axis promotes the bladder cancer development. Clin. Transl. Med. 11(12), e675 (2021).","journal-title":"Clin. Transl. Med."},{"issue":"4","key":"16614_CR74","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3892\/ol.2021.12591","volume":"21","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Methyltransferase-like 1 regulates lung adenocarcinoma A549 cell proliferation and autophagy via the AKT\/mTORC1 signaling pathway. Oncol. Lett. 21(4), 330 (2021).","journal-title":"Oncol. Lett."},{"issue":"3","key":"16614_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cac2.12273","volume":"42","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Aberrant translation regulated by METTL1\/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression. Cancer Commun. (Lond) 42(3), 223\u2013244 (2022).","journal-title":"Cancer Commun. (Lond)"},{"key":"16614_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101423","volume":"20","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. TSPAN31 regulates the proliferation, migration, and apoptosis of gastric cancer cells through the METTL1\/CCT2 pathway. Transl. Oncol. 20, 101423 (2022).","journal-title":"Transl. Oncol."},{"issue":"1","key":"16614_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40364-021-00278-9","volume":"9","author":"Y Cai","year":"2021","unstructured":"Cai, Y. et al. Novel insights into the m(6)A-RNA methyltransferase METTL3 in cancer. Biomark Res. 9(1), 27 (2021).","journal-title":"Biomark Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16614-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:03:09Z","timestamp":1758888189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16614-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16614"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16614-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required for this study as it did not involve human participants or animal subjects. All cell lines used in this study (HepG2 and SNU-449) were purchased from the American Type Culture Collection (ATCC), a certified biological resource center. The cell lines were authenticated by ATCC using short tandem repeat (STR) profiling and were routinely tested for mycoplasma contamination, with negative results prior to experimentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"33087"}}